SCHEMBL25555258

SCHEMBL25555258

C=C(CCC(C)C)c1ccc(OC)c(F)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.50
LMNA P02545 2/20 0.50
MAPK1 P28482 2/20 0.50
RAB9A P51151 1/20 0.50
TAS1R3 Q7RTX0 1/20 0.48
TAS1R1 Q7RTX1 1/20 0.48
HRH3 Q9Y5N1 2/20 0.43
PDE4D Q08499 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
PDE4A P27815 2/20 0.40
PDE4B Q07343 2/20 0.40
PDE4C Q08493 2/20 0.40
MAPT P10636 2/20 0.40
ALDH1A1 P00352 1/20 0.40
ACHE P22303 1/20 0.40
GRM2 Q14416 1/20 0.37
KCNQ3 O43525 1/20 0.36
KCNQ2 O43526 1/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25183753 0.82 HTT (0.58) HTTLMNAMAPK1RAB9ATAS1R3
SCHEMBL16795557 0.80 HTT (0.57) HTTLMNAMAPK1RAB9ATAS1R3
SCHEMBL991185 0.78 HTT (0.56) HTTLMNAMAPK1RAB9ATAS1R3
SCHEMBL8035601 0.77 HTT (0.55) HTTLMNAMAPK1RAB9ATAS1R3
SCHEMBL23891722 0.76 MAOA (0.45) LMNATAS1R3TAS1R1MEN1KMT2A
SCHEMBL15691255 0.74 HTT (0.68) HTTLMNAMAPK1RAB9ATAS1R3
SCHEMBL23891634 0.74 MAOA (0.47) RAB9AALDH1A1SMN1; SMN2
SCHEMBL23891544 0.72 CES2 (0.43)
SCHEMBL9077380 0.71 HTT (0.45) HTTLMNAMAPK1RAB9ATAS1R3
SCHEMBL23891540 0.71 CES2 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 HTT 1458/4885LMNA 2647/4885MAPK1 1701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.